On Tuesday, Shares of Yahoo! Inc. (NASDAQ:YHOO), gained 0.55% to $43.84.
Yahoo, CEO Marissa Mayer will take part in a question-and-answer session at the J.P. Morgan Global Technology, Media and Telecom Conference in Boston.
The session is planned to start on Tuesday, May 19, 2015, at 5:40 a.m. PT / 8:40 a.m. ET.
Yahoo! Inc. provides search and display advertising services on Yahoo properties and associate sites worldwide. The company offers Yahoo Search that serves as a starting point to navigate the Internet and discover information; and Yahoo Answers, which enables users to seek, discover, and share knowledge and opinions across mobile phones, tablets, and desktops.
Shares of Cigna Corp. (NYSE:CI), inclined 2.77% to $131.86, during its last trading session.
Cigna Corporation, declared that Tom McCarthy, Executive Vice President and Chief Financial Officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015 in Las Vegas, NV.
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The company’s Commercial segment offers insured and self-insured customers medical, dental, behavioral health, and vision, in addition to prescription drug benefit plans, health advocacy programs, and other products and services.
At the end of Tuesday’s trade, Shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), gained 0.11% to $9.10.
ARIAD Pharmaceuticals, and Gen Ilac, a leading Turkish pharmaceutical company focused on the supply of orphan drugs for the treatments of rare diseases, declared that ARIAD has granted Gen Ilac exclusive rights to distribute Iclusig® (ponatinib) in Turkey for patients with Philadelphia-positive leukemias.
Gen Ilac was granted the exclusive right to sell Iclusig as an investigational product in Turkey on a named-patient basis and will provide associated medical affairs and regulatory support. ARIAD retains the option to file for marketing authorization at a later date and, if approved, to hold the Marketing Authorization for Iclusig in Turkey. Gen Ilac has the exclusive right then to market and commercialize the product upon approval.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
Finally, PDL BioPharma, Inc. (NASDAQ:PDLI), ended its last trade with -1.65% loss, and closed at $6.56.
PDL BioPharma, stated financial results for the first quarter ended March 31, 2015.
Total revenues for the first quarter of 2015 raised nine percent to $149.7 million from $136.8 million in the first quarter of 2014. Revenues for the quarter ended March 31, 2015 comprised of $127.8 million in royalty and license payments from PDL’s licensees to the Queen et al. patents, $11.4 million in net royalty payments from attained royalty rights and a change in fair value of the royalty rights assets, which comprised of about $0.9 million in net cash royalty rights payments, and $10.5 million in interest revenue from notes receivable debt financings to late-state healthcare companies. The first quarter of 2015 royalty revenue growth over the first quarter of 2014 is driven by raised sales of Perjeta®, Xolair®, Kadcyla®, Entyvio®, Actemra® and Tysabri® by PDL’s licensees and a $1.5 million enhance in interest revenue related to acquisitions of new revenue generating assets.
Net income in the first quarter of 2015 was $84.5 million, or $0.50 per diluted share as contrast with net income in the first quarter of 2014 of $72.9 million, or $0.44 per diluted share. The enhance in net income in the first quarter of 2015 over the same period in 2014 is primarily due to the enhance in royalty revenues from the Queen et al. patents.
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
